A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

• Status: Completed
• Trial end date: 2017-10-11
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1, non-randomized, dose-escalating, open label, multi-center study to be conducted in two parts (Part A and Part B). RO6870810 is a small molecule, non-covalent inhibitor of bromodomain and extra-terminal (BET) family of bromodomains. This study is designed to characterize the safety, tolerability, pharmacokinetics and anti-tumor activity of RO6870810 in participants with histologically confirmed solid tumors with progressive disease (PD) which is refractory or intolerant to standard/approved therapies. In Part A, RO6870810 will be administered by subcutaneous (SC) injection daily for either 21 consecutive days in a 28-day cycle or for 14 consecutive days in a 21-day treatment cycle in participants with advanced solid tumor malignancies to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT). In Part B, RO6870810 will be administered at a dose up to the MTD to further characterize the safety profile and biological effect in a subset of participants with advanced solid tumor malignancies. It is anticipated that a total of 84 participants will be enrolled in to this study (54 in Part A and 30 in Part B). In addition, it is expected that up to 20 participants with histologically confirmed nuclear protein in testis (NUT)-midline carcinoma (NMC) with progressive disease requiring therapy will be enrolled in the sub-study of Parts A and B. In addition, up to 20 participants with diffuse large B-cell lymphoma (DLBCL) may be enrolled at selected study sites.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hoffmann-La Roche

Criteria

Inclusion Criteria:

General:

• Participants with solid tumors must have one or more metastatic tumors evaluable or measurable on radiographic imaging

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (or 2 upon approval by the medical monitor)

• Life expectancy of greater than or equal to (>/=) 3 months

• Disease-free of active second/secondary or prior malignancies >/= 2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast

• Adequate hematological, renal, hepatic and coagulation laboratory test results

• Women of child bearing potential and men must agree to use adequate contraception during the study and for 4 months after the last dose of study drug

Advanced Solid Malignancies:

• Participants with previously treated, histologically confirmed advanced solid malignancy with progressive disease requiring therapy

• Participants must be refractory or intolerant to standard therapy

NUT-midline carcinoma:

• Participants with histologically confirmed newly diagnosed or relapsed/refractory NMC with PD requiring therapy

• Diagnosis of one of the following is required:

1. NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by Immunohistochemistry (IHC) and/or;

2. Detection of NUT gene translocation as determined by Fluorescence In-Situ Hybridization (FISH) Advanced Aggressive DLBCL

• Histologically confirmed advanced aggressive B-cell lymphoma with abnormal MYC expression with persistent disease requiring treatment

• Participants must have relapsed or progressed after at least 2 lines of prior therapy and not eligible for any curative treatment

• Participants must have measurable disease

Exclusion Criteria:

• Participants with hematologic malignancies

• New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia

• Have Fridericia-corrected QT interval (QTcF) greater than (>) 470 milliseconds (msec) (female) or > 450 (male), or history of congenital long QT syndrome

• Active, uncontrolled bacterial, viral, or fungal infections

• Known clinically important respiratory impairment

• Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies

• History of major organ transplant

• History of an autologous or allogeneic bone marrow transplant. For DLBCL participants only: DLBCL participants may have had a previous autologous transplant but not within 90 days of study entry

• Symptomatic central nervous system malignancy or metastasis

• Pregnant or nursing

• Treatment with surgery or chemotherapy within 28 days prior to study entry

• Prior treatment with small molecule (BET) family inhibitor

• Radiation for symptomatic lesions within 14 days of study enrollment